Page 44 - Diamicron MR MIG Cycle 2(20-21) Final

Visual Aids Page 3

Page 3 – Powerful HbA1c Control:

According to real-world evidence from UK, patient will get better chance to achieve HBA1c target 7%
when they are taking Diamicron MR 60.

Compare to patients taking sitagliptin, patients with Diamicron MR 60 have +35% more chance to
achieve HbA1c target 7%.

This difference become more significant when patients need better efficacy to reduce HbA1c up to ≤
6.5%, you will find patients with Diamicron MR 60 have +51% more chance to achieve HbA1c ≤ 6.5%
compare to patients taking Sitagliptin.

To regain your control in Metformin uncontrolled patients, add Diamicron MR 60 early and up titrate
to 2 tablets at breakfast whenever the efficacy is needed.

Objective
To highlight the powerful HbA1c reduction of Diamicron MR over Sitagliptin.

Comments

Use this page to highlight the superior efficacy of Diamicron MR in comparing with Sitagliptin
especially in reduction of HbA1c to <7%.

CPRD New Data
Key End Points

The primary outcome was time to HbA1c level of <7.0% (53 mmol/mol).
Secondary outcomes included time to HbA1c ≤6.5% (48 mmol/mol) and time to ≥1% (11 mmol/mol)
HbA1c reduction from baseline, as well as persistence, durability, and hypoglycemic events.
Methodology
This retrospective study was conducted following the RECORD guidelines for conducting and reporting
studies using observational routinely-collected data and a protocol approved by an Independent
Scientific Advisory Committee (ISAC; protocol Research Datalink (CPRD) to define a cohort of adult
patients with T2D and glycated haemoglobin (HbA1c) level of ≥7.0% (53 mmol/mol) newly treated
with either gliclazide MR or sitagliptin as second-line treatment after metformin monotherapy.
Patients were 1:1 matched using high-dimensional propensity score matching and followed up until
time to first HbA1c <7.0%.